Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome

JP Després, I Lemieux, A Pascot… - … , and vascular biology, 2003 - Am Heart Assoc
Recent data from Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial
(VA-HIT) have recently reported that pharmacological treatment with a fibrate (gemfibrozil) …

IgG is higher in South Asians than Europeans: does infection contribute to ethnic variation in cardiovascular disease?

CM Fischbacher, R Bhopal, CC Blackwell… - … , and vascular biology, 2003 - Am Heart Assoc
Recent data from Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial
(VA-HIT) have recently reported that pharmacological treatment with a fibrate (gemfibrozil) …

The Effect of Fenofibrate on the Levels of High Sensitivity C‐Reactive Protein in Dyslipidemic Obese Patients

E Coban, R Sari - Endocrine research, 2004 - Taylor & Francis
It is now well documented that obesity is associated with a chronic low‐grade inflammatory
state. Levels of high‐sensitivity C‐reactive protein, a marker of systemic inflammation and a …

Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity

DC Chan, GF Watts, PHR Barrett, LJ Beilin… - Clinical …, 2002 - academic.oup.com
Background: Chronic low-grade inflammation may contribute to the increased risk of
atherosclerosis in visceral obesity. Statin and fish oil have been reported to have …

Association of statins with inflammatory cytokines: a population-based Colaus study

T Lyngdoh, P Vollenweider, G Waeber… - Atherosclerosis, 2011 - Elsevier
PURPOSE: A pleiotropic effect of statins has been reported in numerous studies. However,
the association between statin use and inflammatory cytokines is controversial. We …

Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial

IJ Jonkers, MF Mohrschladt, RG Westendorp… - The American journal of …, 2002 - Elsevier
PURPOSE: To determine whether hypertriglyceridemia is associated with systemic
inflammation, which may contribute to the increased cardiovascular risk in patients who …

Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome

RS Rosenson, AL Huskin, DA Wolff, IB Helenowski… - Atherosclerosis, 2008 - Elsevier
OBJECTIVE: To examine the effects of fenofibrate (160mg/d) therapy on fasting and
postprandial cytokine production in subjects with metabolic syndrome and …

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome

R Belfort, R Berria, J Cornell… - The Journal of Clinical …, 2010 - academic.oup.com
Context: Fenofibrate is a peroxisome proliferator-activated receptor α agonist widely used in
clinical practice, but its mechanism of action is incompletely understood. Objective: The aim …

[HTML][HTML] Influence of lipid-lowering drugs on inflammation: what is yet to be done?

S Ugovšek, J Zupan, AR Likozar… - Archives of Medical …, 2022 - ncbi.nlm.nih.gov
Atherosclerosis is a chronic inflammatory disease that is associated with risk of
cardiovascular events. The best-characterised and well-standardised clinical indicator of …

Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients

CJ Kim - Journal of cardiovascular pharmacology, 2006 - journals.lww.com
We investigated the effects of fenofibrate on C-reactive protein (CRP) levels in patients with
hypertriglyceridemia. Patients with a triglyceride level≥ 200 mg/dL were randomly assigned …